{"nctId":"NCT01788046","briefTitle":"Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","startDateStruct":{"date":"2013-03-12","type":"ACTUAL"},"conditions":["Hyperparathyroidism, Secondary"],"count":515,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Etelcalcetide","type":"EXPERIMENTAL","interventionNames":["Drug: Etelcalcetide"]}],"interventions":[{"name":"Etelcalcetide","otherNames":["AMG 416"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.\n* Subject is 18 years of age or older.\n* Subject agrees to not participate in another study of an investigational agent during the study.\n* Subject must be receiving hemodialysis 3 times weekly for at least 3 months\n* Other Inclusion Criteria may apply\n\nExclusion Criteria:\n\n* Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.\n* Other investigational procedures while participating in this study are excluded.\n* Anticipated or scheduled parathyroidectomy during the study period.\n* Subject has received a parathyroidectomy within 3 months prior to dosing.\n* Anticipated or scheduled kidney transplant during the study period.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.\n* Subject has participated in a prior clinical trial of AMG 416\n* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.\n* Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.\n* Other Exclusion Criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase","description":"Participants who did not have any scheduled assessments during the EAP were considered non-responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"75.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mean Predialysis Parathyroid Hormone â‰¤ 300 pg/mL During the Efficacy Assessment Phase","description":"Participants who had no scheduled assessments during the EAP were considered non-responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.72","spread":"2.50"},{"groupId":"OG001","value":"-57.39","spread":"1.91"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.29"},{"groupId":"OG001","value":"-6.69","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":"1.42"},{"groupId":"OG001","value":"-15.84","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"1.42"},{"groupId":"OG001","value":"-9.63","spread":"1.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":259},"commonTop":["Blood calcium decreased","Diarrhoea","Muscle spasms","Nausea","Headache"]}}}